Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience

[1]  Sara R. Selitsky,et al.  CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  W. Symmans,et al.  Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  S. Góźdź,et al.  Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach , 2021, Diagnostics.

[4]  Zhen Zhang,et al.  Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis , 2020, The Journal of international medical research.

[5]  Peter H. Hu,et al.  Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis , 2020, Cancer Research.

[6]  J. S. Lee,et al.  Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges , 2020, Cancers.

[7]  M. Bani,et al.  Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer , 2018, BMC Cancer.

[8]  A. Matsui,et al.  Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer , 2017, Oncology letters.

[9]  Sung-Bae Kim,et al.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.

[10]  J. Balko,et al.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.

[11]  J. Lubiński,et al.  Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients , 2014, Breast Cancer Research and Treatment.

[12]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[13]  R. Wenstrup,et al.  Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer , 2012, Cancer.

[14]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..